Legend Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Legend Biotech Corp
LEGN Stock  USD 56.61  2.53  4.28%   
Legend Biotech financial statements provide useful quarterly and yearly information to potential Legend Biotech Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Legend Biotech financial statements helps investors assess Legend Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Legend Biotech's valuation are summarized below:
Gross Profit
-284 M
Profit Margin
(1.36)
Market Capitalization
10.8 B
Enterprise Value Revenue
30.324
Revenue
342.8 M
We have found one hundred twenty available fundamental ratios for Legend Biotech, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Legend Biotech's last-minute fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 27th of July 2024, Market Cap is likely to drop to about 5.7 B. In addition to that, Enterprise Value is likely to drop to about 5.2 B

Legend Biotech Total Revenue

299.4 Million

Check Legend Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Legend Biotech's main balance sheet or income statement drivers, such as Tax Provision of 268.9 K, Interest Expense of 22.9 M or Selling General Administrative of 112.1 M, as well as many indicators such as Price To Sales Ratio of 70.16, Dividend Yield of 0.0 or PTB Ratio of 8.04. Legend financial statements analysis is a perfect complement when working with Legend Biotech Valuation or Volatility modules.
  
Check out the analysis of Legend Biotech Correlation against competitors.

Legend Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets938.8 M1.8 B572.3 M
Slightly volatile
Other Current Liabilities147.9 M140.1 M94.7 M
Slightly volatile
Total Current Liabilities203.5 M216.4 M124.2 M
Slightly volatile
Other Liabilities6.7 M7.1 M164.9 M
Slightly volatile
Accounts Payable13.6 M20.2 M8.7 M
Slightly volatile
Cash1.3 B1.3 B324.1 M
Slightly volatile
Other Assets0.951.012.6 M
Pretty Stable
Cash And Short Term Investments1.4 B1.3 B366 M
Slightly volatile
Net Receivables164.9 M157.1 M163 M
Slightly volatile
Long Term Debt Total3.4 M5.8 M2.3 M
Slightly volatile
Inventory20.4 M19.4 M3.7 M
Slightly volatile
Total Liabilities522 M589.9 M362 M
Slightly volatile
Total Current Assets770.5 M1.5 B486 M
Slightly volatile
Intangible Assets163 M155.3 M22.6 M
Slightly volatile
Common Stock29.4 K36 K23.8 K
Slightly volatile
Property Plant Equipment100.7 M184.9 M57 M
Slightly volatile
Short and Long Term Debt Total345.1 M328.7 M75.3 M
Slightly volatile
Property Plant And Equipment Net135 M189.7 M75.8 M
Slightly volatile
Current Deferred Revenue34.2 M53 M40.9 M
Very volatile
Non Current Assets Total194.9 M350.8 M138.3 M
Slightly volatile
Non Currrent Assets Other160 M152.4 M26.7 M
Slightly volatile
Common Stock Total Equity24.6 K31.1 K22.4 K
Slightly volatile
Common Stock Shares Outstanding151.5 M176.1 M118.6 M
Slightly volatile
Short Term Investments29.5 M31 M44.9 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1.8 B681.3 M
Slightly volatile
Non Current Liabilities Total339.7 M373.5 M285.5 M
Slightly volatile
Capital Lease Obligations49.7 M47.3 M11.4 M
Slightly volatile
Other Current Assets11.6 M12.2 M115.1 M
Slightly volatile
Property Plant And Equipment Gross140.2 M224.7 M77.3 M
Slightly volatile
Capital Stock30.6 K36 K23.8 K
Slightly volatile
Net Working Capital1.3 B1.3 B407.8 M
Slightly volatile
Short Term Debt1.9 M3.2 M1 M
Slightly volatile
Non Current Liabilities Other53.2 K56 K205.1 M
Slightly volatile
Long Term Debt243 M281.3 M148.7 M
Slightly volatile

Legend Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative112.1 M106.8 M26.1 M
Slightly volatile
Total Revenue299.4 M285.1 M77.5 M
Slightly volatile
Other Operating Expenses365.7 M727.4 M179.6 M
Slightly volatile
Interest Income44.2 M42.1 M10.6 M
Slightly volatile
Depreciation And Amortization12.8 M20.5 M6.4 M
Slightly volatile
Selling And Marketing Expenses67.2 M94.2 M29.5 M
Slightly volatile
Research Development272.4 M382.2 M149.6 M
Slightly volatile
Total Operating Expenses384.4 M562.7 M199.7 M
Slightly volatile
Reconciled Depreciation12.7 M20.3 M6.4 M
Slightly volatile
Cost Of Revenue155.1 M164.7 M216.8 M
Slightly volatile

Legend Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock1.1 M1.3 M1.4 M
Slightly volatile
Depreciation11 M20.5 M5.5 M
Slightly volatile
Capital Expenditures127.6 M121.5 M29 M
Slightly volatile
Change To Operating Activities143.4 M136.6 M41.5 M
Slightly volatile
Total Cash From Financing Activities831.1 M791.5 M219.3 M
Slightly volatile
End Period Cash Flow1.3 B1.3 B324.1 M
Slightly volatile
Stock Based Compensation50.1 M47.7 M11 M
Slightly volatile
Begin Period Cash Flow408.4 M787.3 M176.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio70.1637.156470.3532
Slightly volatile
Days Sales Outstanding349201580
Slightly volatile
Stock Based Compensation To Revenue0.120.16720.0727
Slightly volatile
Capex To Depreciation6.55.94139.4603
Slightly volatile
EV To Sales65.4933.826966.1117
Slightly volatile
Inventory Turnover8.058.4735108
Slightly volatile
Days Of Inventory On Hand45.2343.075611.9527
Slightly volatile
Payables Turnover7.768.167936.6634
Slightly volatile
Sales General And Administrative To Revenue0.270.37440.1858
Slightly volatile
Research And Ddevelopement To Revenue1.981.34041.7788
Slightly volatile
Capex To Revenue0.540.42610.4582
Pretty Stable
Cash Per Share7.817.43443.5265
Slightly volatile
Days Payables Outstanding48.9644.687125.0746
Slightly volatile
Intangibles To Total Assets0.08820.0840.0135
Slightly volatile
Net Debt To EBITDA2.142.25117.8181
Slightly volatile
Current Ratio7.276.92093.0035
Slightly volatile
Receivables Turnover1.721.815587.4385
Slightly volatile
Graham Number22.7821.6946.2951
Slightly volatile
Capex Per Share0.720.69010.2996
Slightly volatile
Revenue Per Share1.71.61940.6793
Slightly volatile
Interest Debt Per Share1.831.73950.4542
Slightly volatile
Debt To Assets0.160.15390.0503
Slightly volatile
Operating Cycle268244358
Slightly volatile
Days Of Payables Outstanding48.9644.687125.0746
Slightly volatile
Ebt Per Ebit0.821.17621.0277
Slightly volatile
Quick Ratio7.176.83112.9825
Slightly volatile
Net Income Per E B T1.230.99641.4493
Slightly volatile
Cash Ratio6.25.90562.171
Slightly volatile
Days Of Inventory Outstanding45.2343.075611.9527
Slightly volatile
Days Of Sales Outstanding349201580
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.981.3161.0483
Slightly volatile
Fixed Asset Turnover1.051.50331.2392
Slightly volatile
Debt Ratio0.160.15390.0503
Slightly volatile
Price Sales Ratio70.1637.156470.3532
Slightly volatile
Asset Turnover0.130.15420.1191
Pretty Stable

Legend Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap5.7 B10.6 B4.5 B
Slightly volatile
Enterprise Value5.2 B9.6 B4 B
Slightly volatile

Legend Fundamental Market Drivers

Cash And Short Term Investments1.3 B

Legend Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
16th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Legend Biotech Financial Statements

Legend Biotech investors utilize fundamental indicators, such as revenue or net income, to predict how Legend Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue53 M34.2 M
Total Revenue285.1 M299.4 M
Cost Of Revenue164.7 M155.1 M
Stock Based Compensation To Revenue 0.17  0.12 
Sales General And Administrative To Revenue 0.37  0.27 
Research And Ddevelopement To Revenue 1.34  1.98 
Capex To Revenue 0.43  0.54 
Revenue Per Share 1.62  1.70 
Ebit Per Revenue(1.55)(1.63)

Pair Trading with Legend Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Legend Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Legend Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving together with Legend Stock

  0.71JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr

Moving against Legend Stock

  0.7ALVO AlvotechPairCorr
  0.69ONCT Oncternal TherapeuticsPairCorr
  0.66IMMP Immutep Ltd ADR Earnings Call TomorrowPairCorr
  0.51ENTX Entera BioPairCorr
  0.44MRK Merck Company Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Legend Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Legend Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Legend Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Legend Biotech Corp to buy it.
The correlation of Legend Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Legend Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Legend Biotech Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Legend Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Information and Resources on Investing in Legend Stock

When determining whether Legend Biotech Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Legend Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Legend Biotech Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Legend Biotech Corp Stock:
How To Invest In Legend
Details
Is Legend Stock a good investment?
Details
What is Legend Biotech's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Legend Biotech Correlation against competitors.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.58)
Revenue Per Share
1.902
Quarterly Revenue Growth
1.587
Return On Assets
(0.18)
Return On Equity
(0.51)
The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Legend Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY